|
|
Vaccine Detail
|
Priorix |
| Vaccine Information |
- Vaccine Name: Priorix
- Target Pathogen: Rubella virus
- Target Disease: Rubella
- Product Name: Combined measles, mumps and rubella vaccine, live, attenuated
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0010734
- Type: Live, attenuated vaccine
- Status: Licensed
- Location Licensed: Canada
- Host Species for Licensed Use: Human
- Antigen: Lyophilised mixture of attenuated Schwartz measles (Rampa et al., 2020).
- Allergen: Eggs, Neomycin
- Preparation: Acquired individually by propagation in chick embryo tissue cultures or MRC-5 human diploid cell. Antigen component is reconstituted using sterile water diluent before administered (Rampa et al., 2020).
- Immunization Route: Subcutaneous injection and Intramuscular injection (i.m.)
- Storage: Store at at 2 to 8°C.(Rampa et al., 2020)
- Approved Age for Licensed Use: 1 year and older(Rampa et al., 2020)
- Contraindication: Should not be administered to persons with a history of severe allergic reactions to any component of the vaccine or after a previous dose of any measles, mumps and rubella virus containing vaccine. Pregnancy should be avoided for 1 month after receipt of MMR. (Rampa et al., 2020)
- Description: Priorix is a single dose live attenuated vaccine for active immunization for the prevention of measles mumps, and rubella in individuals 12 months of age and older. (Rampa et al., 2020)
|
| Host Response |
|
|
| References |
|
|
|
